FDA Determines Regulatory Review Period for BRIVIACT ORAL SOLUTION Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for BRIVIACT ORAL SOLUTION, a new drug application submitted to the US Patent and Trademark Office (USPTO), in accordance with federal regulations.